From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunoth...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/2/58 |
| _version_ | 1797298493207871488 |
|---|---|
| author | Kamil J. Synoradzki Natalia Paduszyńska Malgorzata Solnik Mario Damiano Toro Krzysztof Bilmin Elżbieta Bylina Piotr Rutkowski Yacoub A. Yousef Claudio Bucolo Sandrine Anne Zweifel Michele Reibaldi Michal Fiedorowicz Anna M. Czarnecka |
| author_facet | Kamil J. Synoradzki Natalia Paduszyńska Malgorzata Solnik Mario Damiano Toro Krzysztof Bilmin Elżbieta Bylina Piotr Rutkowski Yacoub A. Yousef Claudio Bucolo Sandrine Anne Zweifel Michele Reibaldi Michal Fiedorowicz Anna M. Czarnecka |
| author_sort | Kamil J. Synoradzki |
| collection | DOAJ |
| description | Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA. Another potential approach to treat UM could be based on T cell receptor engineering rather than antibody modification. Immune-mobilizing monoclonal T cell receptors (TCR) against cancer, called ImmTAC TM molecules, represent such an approach. Moreover, nanomedicine, especially miRNA approaches, are promising for future trials. Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research. |
| first_indexed | 2024-03-07T22:36:40Z |
| format | Article |
| id | doaj.art-960539c0f6e54130a155e5bda2dce710 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-07T22:36:40Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-960539c0f6e54130a155e5bda2dce7102024-02-23T15:13:24ZengMDPI AGCurrent Oncology1198-00521718-77292024-02-0131277880010.3390/curroncol31020058From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal MelanomaKamil J. Synoradzki0Natalia Paduszyńska1Malgorzata Solnik2Mario Damiano Toro3Krzysztof Bilmin4Elżbieta Bylina5Piotr Rutkowski6Yacoub A. Yousef7Claudio Bucolo8Sandrine Anne Zweifel9Michele Reibaldi10Michal Fiedorowicz11Anna M. Czarnecka12Environmental Laboratory of Pharmacological and Toxicological Research, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Str., 02-106 Warsaw, PolandFaculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, PolandFaculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, PolandChair and Department of General and Pediatric Ophthalmology, Medical University of Lublin, 1 Chmielna Str., 20-079 Lublin, PolandResearch and Development Centre Novasome Sp. z o.o., 51-423 Wrocław, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Str., 02-781 Warsaw, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Str., 02-781 Warsaw, PolandDepartment of Surgery (Ophthalmology), King Hussein Cancer Centre, Amman 11941, JordanDepartment of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, ItalyDepartment of Ophthalmology, University Hospital Zurich, 8091 Zurich, SwitzerlandDepartment of Surgical Sciences, Eye Clinic Section, Citta della Salute e della Scienza, Turin University, 10122 Turin, ItalySmall Animal Magnetic Resonance Imaging Laboratory, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Str., 02-106 Warsaw, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Str., 02-781 Warsaw, PolandMolecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA. Another potential approach to treat UM could be based on T cell receptor engineering rather than antibody modification. Immune-mobilizing monoclonal T cell receptors (TCR) against cancer, called ImmTAC TM molecules, represent such an approach. Moreover, nanomedicine, especially miRNA approaches, are promising for future trials. Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research.https://www.mdpi.com/1718-7729/31/2/58uveal melanomabiomarkersimmunotherapytheranosticsnanomedicine |
| spellingShingle | Kamil J. Synoradzki Natalia Paduszyńska Malgorzata Solnik Mario Damiano Toro Krzysztof Bilmin Elżbieta Bylina Piotr Rutkowski Yacoub A. Yousef Claudio Bucolo Sandrine Anne Zweifel Michele Reibaldi Michal Fiedorowicz Anna M. Czarnecka From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma Current Oncology uveal melanoma biomarkers immunotherapy theranostics nanomedicine |
| title | From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma |
| title_full | From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma |
| title_fullStr | From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma |
| title_full_unstemmed | From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma |
| title_short | From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma |
| title_sort | from molecular biology to novel immunotherapies and nanomedicine in uveal melanoma |
| topic | uveal melanoma biomarkers immunotherapy theranostics nanomedicine |
| url | https://www.mdpi.com/1718-7729/31/2/58 |
| work_keys_str_mv | AT kamiljsynoradzki frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT nataliapaduszynska frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT malgorzatasolnik frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT mariodamianotoro frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT krzysztofbilmin frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT elzbietabylina frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT piotrrutkowski frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT yacoubayousef frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT claudiobucolo frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT sandrineannezweifel frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT michelereibaldi frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT michalfiedorowicz frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma AT annamczarnecka frommolecularbiologytonovelimmunotherapiesandnanomedicineinuvealmelanoma |